Platelet Function in Patients With an Acute Coronary Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aims of the study are to:

* explore whether platelet reactivity in patients treated wih novel platelet inhibitors is associated with clinical outcome
* investigate whether a therapeutic window exist for novel platelet inhibitors
* investigate the incidence of adverse events under treatment with novel platelet inhibitors in the real life clinical scenario
* investigate the association between genetic polymorphisms, inflammation, platelet reactivity and clinical outcome
* investigate synergistic effects between aspirin and novel platelet inhibitors

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome (ACS)

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

platelets, Acute coronary Syndrome (ACS), prasugrel, ticagrelor, aspirin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent
* Acute coronary syndrome at admission
* Planned treatment with novel platelet inhibitors
* Age \>18

Exclusion Criteria

\* Participation in interventional trials

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jolanta Siller-Matula

PD Dr.med. PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical Univerity of Vienna, Department of Cardiology

Vienna, , Austria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jolanta M Siller-Matula, PD MD PhD

Role: CONTACT

Phone: 0043 1 404004614

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ATLANTIS-ACS

Identifier Type: -

Identifier Source: org_study_id